Utilization of RNAi to Validate Antibodies for Reverse Phase Protein Arrays

  • Heiko Mannsperger
  • Stefan Uhlmann
  • Ulrike Korf
  • Özgür Sahin
Part of the Methods in Molecular Biology book series (MIMB, volume 785)


Reverse phase protein arrays (RPPAs) emerged as a very useful tool for high-throughput screening of protein expression in large numbers of small specimen. Similar to other protein chemistry methods, antibody specificity is also a major concern for RPPA. Currently, testing antibodies on Western blot for specificity and applying serial dilution curves to determine signal/concentration linearity of RPPA signals are most commonly employed to validate antibodies for RPPA applications. However, even the detection antibodies fulfilling both requirements do not always give the expected result. Chemically synthesized small interfering RNAs (siRNAs) are one of the most promising and time-efficient tools for loss-of-function studies by specifically targeting the gene of interest resulting in a reduction at the protein expression level, and are therefore used to dissect biological processes. Here, we report the utilization of siRNA-treated sample lysates for the quantification of a protein of interest as a useful and reliable tool to validate antibody specificity for RPPAs. As our results indicate, we recommend the use of antibodies which give the highest dynamic range between the control siRNA-treated samples and the target protein (here: EGFR) siRNA-treated ones on RPPAs, to be able to quantify even small differences of protein abundance with high confidence.

Key words

Reverse phase protein arrays Antibody validation Antibody specificity Epidermal growth factor receptor RNAi siRNAs 


  1. 1.
    Paweletz, C.P., et al., Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene, 2001. 20(16): 1981–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Charboneau, L., et al., Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic, 2002. 1(3): 305–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Spurrier, B., S. Ramalingam, and S. Nishizuka, Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc, 2008. 3(11): 1796–808.PubMedCrossRefGoogle Scholar
  4. 4.
    Mittal, V., Improving the efficiency of RNA interference in mammals. Nat Rev Genet, 2004. 5(5): 355–65.PubMedCrossRefGoogle Scholar
  5. 5.
    Fire, A., et al., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 1998. 391(6669): 806–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Elbashir, S.M., et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001. 411(6836): 494–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Sahin, O., et al., Combinatorial RNAi for quantitative protein network analysis. Proc Natl Acad Sci USA, 2007. 104(16): 6579–84.PubMedCrossRefGoogle Scholar
  8. 8.
    Sahin, O., et al., Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol, 2009. 3: 1.PubMedCrossRefGoogle Scholar
  9. 9.
    Frohlich, H., et al., Deterministic Effects Propagation Networks for reconstructing protein signaling networks from multiple interventions. BMC Bioinformatics, 2009. 10: 322.PubMedCrossRefGoogle Scholar
  10. 10.
    Spurrier, B., et al., Antibody screening database for protein kinetic modeling. Proteomics, 2007. 7(18): 3259–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Heiko Mannsperger
    • 1
  • Stefan Uhlmann
    • 1
  • Ulrike Korf
    • 1
  • Özgür Sahin
    • 1
  1. 1.Division of Molecular Genome AnalysisGerman Cancer Research Center (DKFZ)HeidelbergGermany

Personalised recommendations